cAMP signaling pathway

The cyclic AMP (cAMP) signaling pathway is a ubiquitous second-messenger cascade in which extracellular signals (hormones, neurotransmitters, metabolic cues) are transduced through G protein-coupled receptors (GPCRs) to cytoplasmic cAMP, which activates protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac). The pathway controls an extraordinarily broad set of outputs — gene transcription via CREB, mitochondrial biogenesis via PGC-1α, lipolysis, exocytosis, neuronal plasticity, and cardiac chronotropy/inotropy — making it a master integrator of hormonal status and energy state. In aging, the pathway shows region- and tissue-specific changes including reduced β-adrenergic responsiveness in cardiac and adipose tissue, blunted pCREB (Ser133) in hippocampus and parietal cortex, and paradoxically elevated cAMP in prefrontal cortex — contributing to metabolic dysfunction, cognitive decline, and impaired stress responses ¹². Hippocampal adenylyl cyclase activity changes are mixed in the literature (approximately half of studies show decline, half show no change) ¹.

Naming note: This page covers the pathway. Individual node pages (when seeded) will live at molecules/proteins/prkaca.md, molecules/proteins/creb1.md, etc. The KEGG pathway identifier hsa04024 covers a broad cAMP effector network; this page focuses on the Gαs/Gαi → adenylyl cyclase → cAMP → PKA + Epac → CREB axis.

Canonical architecture: Gαs/Gαi → AC → cAMP → PKA + Epac

1. GPCR input and G-protein coupling

Extracellular ligands bind GPCRs; the class of G protein alpha subunit engaged determines the direction of cAMP flux:

G-protein class	Direction	Example receptors
Gαs	Adenylyl cyclase activated → cAMP ↑	β1/β2-adrenergic, glucagon (GCGR), GLP-1R, PTH1R, MC1R, MC4R, MC5R, GHSR, adenosine A2AR
Gαi	Adenylyl cyclase inhibited → cAMP ↓	α2-adrenergic, adenosine A1R, opioid receptors, dopamine D2R
Gαq	Phospholipase C activated; no direct cAMP effect	Angiotensin AT1R, muscarinic M1R

The adenylyl cyclases (ADCY1–10) catalyze ATP → cAMP + PPi. Nine of the ten are transmembrane (tmACs); ADCY10 is soluble (sAC, activated by bicarbonate/Ca²⁺). Individual isoforms show tissue-specific expression — ADCY1 and ADCY8 dominate in hippocampal neurons; ADCY5 is the cardiac isoform. needs-canonical-id — no individual protein pages exist yet for ADCY isoforms; the generic [[adcy]] wikilink above is a stub.

2. cAMP production and termination

cAMP is synthesized at the plasma membrane (tmAC) or in intracellular compartments (sAC, near mitochondria). Spatial confinement of cAMP pools is enforced by A-kinase anchoring proteins (AKAPs), which scaffold PKA regulatory subunits near specific substrates, creating distinct functional “signalosomes” ³.

Termination is handled by phosphodiesterases (PDEs), which hydrolyze cAMP → 5’-AMP. PDE4 (ENPP4/PDE4A–D gene products) is the dominant cytosolic cAMP-specific PDE in most tissues; PDE3 (dual-specificity) competes with PDE4 in cardiac myocytes and adipocytes ⁴. Other cAMP-degrading PDEs include PDE7 and PDE8 (both cAMP-selective, low K_m, relatively insensitive to IBMX).

3. PKA: holoenzyme, activation, and substrates

Inactive PKA exists as an R₂C₂ tetramer — two regulatory (R) subunits (RIα, RIβ, RIIα, RIIβ; genes PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B) bound to two catalytic (C) subunits (Cα/PRKACA, Cβ/PRKACB, Cγ/PRKACG). Each R subunit has two cAMP-binding domains (CNB-A and CNB-B); cAMP binding induces conformational release of the C subunits, which then phosphorylate serine/threonine on consensus motifs (R/K–R/K–x–S/T) ⁵.

PKA integrates dual-targeting logic: RI isoforms localize to soluble/cytosolic anchors; RII isoforms partner with AKAP scaffolds at discrete membranes (ER, mitochondria, centrosomes). This explains why the same rise in global cAMP can produce cell-type-specific transcriptional vs. metabolic vs. structural outputs depending on which R isoforms are expressed and which AKAPs are present.

Key PKA substrates in aging-relevant contexts:

Substrate	Effect of phosphorylation	Aging context
CREB1 (Ser133)	Recruits CBP/p300 coactivator → transcription of CRE-containing genes	Memory consolidation, PGC-1α induction — pCREB declines in aged rodent hippocampus and parietal cortex (mixed evidence for AC activity decline; see §Hippocampal cAMP-CREB axis) ¹
CRTC1/2/3	De-repressed from 14-3-3 cytoplasmic retention → nuclear → CREB co-activation	Synaptic plasticity, gluconeogenesis control
Phospholamban (PLN Ser16)	SERCA2a activity ↑ → Ca²⁺ reuptake into SR → cardiac relaxation	Cardiac aging; PKA-PLN axis in inotropic reserve
HSL (Ser563)	Hormone-sensitive lipase activated → triglyceride hydrolysis	Lipolysis in adipocytes; blunted in aged fat ²
VASP, RYR2, L-type VGCC	Ion channel/cytoskeletal phosphorylation	Cardiac excitation-contraction coupling

4. Epac: PKA-independent cAMP effector

Epac1 (RAPGEF3) and Epac2 (RAPGEF4) are cAMP-binding guanine nucleotide exchange factors for Rap1/2 (small GTPases of the Ras superfamily) ⁶. Unlike PKA, Epac does not phosphorylate CREB; instead, Rap1/Rap2 activation modulates cell adhesion (integrin signaling), insulin secretion (Epac2 in β-cells), and — in cardiomyocytes — a PKA-independent phospholamban phosphorylation through CaMKII ⁷. Epac1-knockout mice are protected against age- and stress-induced cardiomyopathy in some models ⁷, suggesting Epac1 may amplify maladaptive cardiac remodeling independently of PKA. needs-replication — cardiac protection in Epac1-KO has not been extended to aging-specific longevity outcomes.

5. CREB → downstream gene programs

Phospho-CREB (pCREB, Ser133) binds the cAMP response element (CRE; consensus 5’-TGACGTCA-3’) in promoters of target genes. Key downstream programs include:

PGC-1α (PPARGC1A) — mitochondrial biogenesis master regulator; CREB drives PGC-1α transcription in response to exercise, cold, and fasting cues (see mitochondrial-biogenesis)
BDNF (brain-derived neurotrophic factor) — neuroprotective; declines with age; CREB-dependent induction supports synaptic plasticity
c-Fos, Fosb, Jun — IEG (immediate-early gene) transcription factors; secondary wave of AP-1-dependent gene regulation
NR4A1/2/3 (Nur77/Nurr1/NOR-1) — orphan nuclear receptors; anti-inflammatory, metabolic, dopaminergic
CART, pro-opiomelanocortin (POMC) — neuropeptide precursors; cAMP drives POMC transcription in response to MC4R activation (see melanocortin-system)

Co-activator CBP (CREBBP) is recruited by pCREB; additional co-activation is provided by CRTC1–3 (CREB-regulated transcription coactivators), whose nuclear translocation is derepressed when PKA phosphorylates 14-3-3 release sites on CRTC.

Role in aging

β-Adrenergic responsiveness declines with age

One of the most replicated cAMP-pathway aging phenotypes is reduced β-adrenergic response in cardiac and adipose tissue. In aged hearts, β1-AR density decreases, G-protein coupling efficiency falls, and maximal cAMP production after β-agonist stimulation is attenuated — leading to blunted inotropic reserve ⁸. The mechanism involves multiple nodes: increased GRK2 (β-ARK1)-mediated receptor desensitization, upregulation of inhibitory Gαi, reduced adenylyl cyclase (AC5/AC6) expression, and increased PDE4D activity that accelerates cAMP hydrolysis before it can diffuse to effectors ⁴.

PKA loss-of-function mouse models extend lifespan: PKA RIIβ-knockout C57BL/6J males show extended lifespan and resistance to cardiac hypertrophy, diastolic dysfunction, and obesity-related metabolic decline ². Separately, AC5-knockout (type 5 adenylyl cyclase disruption) mice show approximately 30% median lifespan extension, improved exercise tolerance, and resistance to heart failure and obesity in the Yan 2007 study cited within Enns 2010 ⁹. Both models invert the intuitive frame: reducing upstream cAMP-pathway activity is cardioprotective and pro-longevity; the mechanism is context- and tissue-specific. needs-human-replication — AC5-KO and PKA-KO longevity evidence is from mice only.

Hippocampal cAMP-CREB axis and cognitive aging

Age-related memory decline correlates with reduced cAMP-CREB signaling in the hippocampus, though the picture is mixed and region-specific. Kelly 2018 surveyed human and rodent data and found that: approximately half of animal studies show age-related reductions in hippocampal AC activity and the other half show no change; basal cAMP levels do not consistently change with age in rodent hippocampus; PKA activity is significantly decreased in prefrontal cortex and hippocampus of aged rodents; and pCREB (Ser133) immunoreactivity declines in aged rodent hippocampus and parietal cortex. Critically, the review notes that prefrontal cAMP increases with age (the opposite pattern), correlating with cognitive deficits through a different mechanism — so the effect is brain-region-specific and not a uniform decline ¹. In Alzheimer’s disease, tau accumulation in hippocampal neurons suppresses PKA via nuclear proteasome-dependent upregulation of the PKA regulatory subunit PKAR2α specifically in the nuclear fraction — caused by disruption of the PA28γ-20S proteasome complex that normally degrades PKAR2α — blocking CREB phosphorylation and reducing glutamate receptor (GluA1) surface expression ¹⁰.

The CREB-BDNF arm is particularly relevant: CREB-driven BDNF transcription is necessary for the late phase of LTP (L-LTP); failure of this transcriptional response may be one of the earliest functional deficits in normal cognitive aging before any overt pathology. no-mechanism — the upstream cause of hippocampal pCREB decline is not established; candidates include reduced norepinephrine tone, oxidative inactivation of AC1/AC8, and membrane-lipid remodeling that alters AC accessibility. contradictory-evidence — Kelly 2018 found that roughly half of studies showed no age-related AC activity change in hippocampus, so the AC-activity-decline framing is contested.

cAMP-PGC-1α and mitochondrial biogenesis in aging

Exercise-induced cAMP (via β-agonist/catecholamine release) activates PKA → CREB → PGC-1α → mitochondrial biogenesis transcription program. In aged rodent skeletal muscle, this cascade is impaired: pCREB induction after exercise is attenuated, PGC-1α upregulation is blunted, and mitochondrial content recovers more slowly ¹¹. Pharmacological cAMP elevation with pentoxifylline (a non-selective PDE inhibitor) in D-galactose-accelerated aging CD1/ICR mice (60 mg/kg/d i.p., 4 weeks) increased pCREB and PGC-1α protein levels, restored Nrf2-mediated antioxidant gene expression (HO-1, NQQ1, SOD2, CAT), and improved markers of mitochondrial biogenesis (citrate synthase activity, mtDNA copy number, TFAM) in hippocampus ¹². needs-human-replication — these effects have not been recapitulated in controlled human trials with aging endpoints.

Lipolytic cAMP signaling and metabolic aging

Catecholamine-stimulated lipolysis depends on the β-AR → cAMP → PKA → hormone-sensitive lipase (HSL) axis. Aging is associated with a lipolytic defect in adipose tissue: reduced β-AR density, lower AC coupling efficiency, and higher basal PDE activity all contribute to a blunted cAMP rise after adrenergic stimulation, thereby impairing triglyceride mobilization during fasting or exercise. This lipolytic resistance may contribute to the accumulation of visceral fat in older adults and downstream metabolic aging. unsourced — specific RCT-level human evidence quantifying the cAMP amplitude reduction in aged human adipocytes is lacking; cited above as mechanistic inference from rodent studies.

PKA, sirtuins, and longevity (C. elegans)

In C. elegans, hydralazine binds and stabilizes the PKA catalytic subunit (PRKACA/KIN-1), causing dissociation of the regulatory subunit and thereby activating PKA — which in turn phosphorylates and activates SIRT1 (SIR-2.1) in a NAD-independent manner, and SIRT5 (which deacetylates CPS1 and other mitochondrial targets), leading to improved mitochondrial function and median lifespan extension of approximately 25% ¹³. The mechanism is PKA activation, not inhibition — hydralazine’s longevity benefit requires PKA (abrogated in KIN-1 knockdown worms). This positions PKA as a longevity-promoting kinase in C. elegans, in contrast to the mammalian cardiac context where PKA/AC5 over-activity is pro-aging. Whether hydralazine-PKA-SIRT1/5 axis is conserved in mammals as a longevity-relevant pathway is not established. needs-human-replication

Compartmentalization and microdomains

A critical contemporary insight is that cAMP does not act as a freely diffusing global second messenger. Instead, AKAP scaffolds (e.g., mAKAP/AKAP6 in cardiac myocytes; AKAP79/150 in neurons) tether PKA regulatory subunits and PDEs into proximity, creating cAMP microdomains where local signal amplitude is decoupled from bulk cytosolic cAMP ³. In cardiac hypertrophy and heart failure, the balance of PDE3 vs. PDE4 anchoring to these complexes shifts, altering the local cAMP waveform even when total cAMP is unchanged ⁴. This compartmentalization model has major implications for aging: a “decline in cAMP signaling” may not mean a uniform fall, but a redistribution of subcellular cAMP pools with some pools hyperactivated and others silenced.

Pharmacological landscape

Drug class	Examples	Mechanism	Aging relevance
Non-selective PDE inhibitor	Theophylline, caffeine, pentoxifylline	Block PDE1–5; global cAMP ↑	Cognitive/mitochondrial effects in aging models; limited by toxicity at high dose
PDE4-selective inhibitor	Roflumilast (COPD-approved), apremilast (PsA-approved)	Block PDE4A–D → cAMP ↑ in immune/inflammatory cells	Aging trial: rolipram improved memory in aged rats; roflumilast explored for neuroinflammation
PDE5 inhibitor	Sildenafil, tadalafil	Block PDE5 (cGMP-specific) — minimal direct cAMP effect	Note: often grouped with cAMP-raising drugs but the primary effector is cGMP/PKG, not cAMP
β-agonists	Salmeterol, formoterol, clenbuterol	Activate β2-AR → Gαs → AC → cAMP ↑	Explored for sarcopenia (anabolic via PKA → mTOR); off-target cardiac risks limit aging use
GLP-1 receptor agonists	Semaglutide, liraglutide	GLP-1R → Gαs → cAMP → PKA + Epac2 (pancreatic β-cell)	Geroprotective evidence accumulating; cAMP mechanism is pancreatic and extra-pancreatic
β-blockers	Metoprolol, carvedilol	Block β-AR → reduce cAMP in heart	Standard HF/cardiac aging management; geroprotective in the hyperadrenergic-aging frame
Adenylyl cyclase activator	Forskolin (non-clinical tool compound)	Directly activates tmAC	Used as experimental cAMP elevator; no approved aging indication

Druggability-tier rationale (tier 1): Multiple FDA-approved drugs modulate this pathway in aging-relevant contexts — β-blockers (standard of care in cardiac aging), GLP-1 agonists (approved, emerging broad-organ effects), and PDE4 inhibitors (roflumilast FDA-approved). The aging-context tier is 1. dose-response-unclear — optimal cAMP modulation amplitude for geroprotection in any tissue is not established.

Cross-pathway connections

ampk — cAMP/PKA and AMPK share a bidirectional relationship. Elevated cAMP → PKA → phosphorylates and activates AMPK in some cell types; conversely, AMPK activation can suppress β-AR desensitization. Both respond to energy stress but with different kinetics and tissue specificity. See ampk for the canonical AMPK-cAMP intersection.
mtor — CREB-driven PGC-1α is a nexus with mTOR biology: mTORC1 promotes anabolic translation while PGC-1α drives mitochondrial capacity. cAMP and mTOR signaling are partially antagonistic in some contexts (PKA can activate Rheb in some tissues, countering AMPK suppression of mTOR).
insulin-igf1 — Insulin/IGF-1 signaling can inhibit cAMP via Gαi-coupled cross-talk (PI3K-activated PDE3B in adipocytes, suppressing PKA-mediated lipolysis). Counter-regulation of lipolysis by insulin is the major physiological example.
melanocortin-system — MC1R, MC4R, MC5R are all Gαs-coupled; their downstream effects (pigmentation, appetite suppression, metabolic rate, sebaceous gland lipid regulation) are cAMP-mediated. See melanocortin-system for the melanocortin-cAMP network detail.
sirtuin — PKA-SIRT1 interaction (PKA directly phosphorylates and activates SIRT1 in a NAD-independent manner; conversely, NAD+ availability links SIRT1 activity to metabolic state). Hydralazine-PKA activation → SIRT1/SIRT5 axis in C. elegans provides a longevity-relevant link ¹³.
ras-mapk — Epac1/2 activates Rap1, which can suppress Raf1 → MEK → ERK, providing inhibitory cross-talk from cAMP to the proliferative MAPK cascade. Separate from PKA-mediated MEK inhibition via B-Raf phosphorylation.

Limitations and gaps

Tissue heterogeneity: cAMP effects are entirely context-dependent. Cardiac AC5 KO extends lifespan ⁹; hippocampal AC1/AC8 activity supports memory ¹. A systemic cAMP “raiser” would have opposing effects in these tissues simultaneously. No geroprotection strategy can target cAMP globally. no-mechanism
Compartmentalization is under-characterized in aged tissue: Whether AKAP scaffold composition changes with age — altering the spatial map of cAMP microdomains — is largely unknown. needs-replication
CREB decline causality not established: CREB phosphorylation declines with age, but MR evidence that restoring pCREB causes cognitive preservation in humans is absent. no-mechanism
Human aging-specific clinical data is sparse: Most mechanistic data is from rodent models; GLP-1 agonist and PDE4 inhibitor human trials have not been powered for aging endpoints. needs-human-replication
Epac aging biology is nascent: Epac1/2 roles in aging-specific phenotypes are largely unstudied outside the cardiac stress model. unsourced

Footnotes

doi:10.1016/j.cellsig.2017.11.004 · PMID:29175000 · PMC:PMC5732030 · review · model: human + rodent brain aging · mixed finding: ~half of studies show hippocampal AC activity decline with age, ~half show no change; basal cAMP does not consistently fall; PKA activity reduced in hippocampus and prefrontal cortex; pCREB declines in hippocampus/parietal cortex; prefrontal cAMP paradoxically increases with age; effect is brain-region-specific; download failed (green OA, PMC fallback used) ↩ ↩² ↩³ ↩⁴ ↩⁵
doi:10.18632/aging.100138 · PMID:20448293 · in-vivo (mouse) · model: C57BL/6 (PKA RIIβ-KO and Cβ-KO; NOT AC5-KO) · RIIβ-KO C57/BL6J males: extended lifespan, cardiac hypertrophy suppressed, diastolic dysfunction suppressed; Cβ-KO: obesity resistance, hepatoprotection, improved cardiac function; PKA identified as aging target; n=not stated in paper (retrospective perspective); AC5-KO data is from Yan 2007 (ref 9 in Enns 2010), not this paper ↩ ↩² ↩³
doi:10.1124/molpharm.120.000197 · PMID:33574048 · review · model: biochemical / pharmacological · AKAP-mediated cAMP compartmentalization; PDE inhibitor approach to phosphoproteomic dissection of cAMP-dependent signaling ↩ ↩²
doi:10.1016/j.yjmcc.2020.10.011 · PMID:33184031 · in-vitro + in-vivo (rat/mouse) · model: cardiac hypertrophy model · PDE3/PDE4 balance shifts in hypertrophy, altering local cAMP pool dynamics ↩ ↩² ↩³
doi:10.1016/j.bbapap.2013.03.007 · PMID:23535202 · PMC:PMC3763834 · review · model: biochemical / structural · PKA holoenzyme structure (R₂C₂ tetramer), regulatory subunit isoforms (RIα, RIβ, RIIα, RIIβ — functionally non-redundant), AKAP anchoring logic (amphipathic helix binds D/D domain of R-subunit dimer); 20-year retrospective (“Lessons Learned after Twenty Years”); download failed (green OA, PMC fallback used); catalytic subunit isoform listing (Cα/Cβ/Cγ) confirmed in Enns 2010 text, not independently in Taylor 2013 PMC text ↩
doi:10.1016/j.tibs.2006.10.002 · PMID:17084085 · review · model: biochemical / cell biology · Epac1/2 as cAMP-GEFs for Rap1/Rap2; PKA-independent cAMP effector functions; not_oa in archive unverified-source ↩
doi:10.1172/JCI64784 · PMID:24892712 · in-vivo (mouse) · model: Epac1-KO mouse (cardiac stress/aging) · Epac1-KO protects against stress-induced cardiomyopathy via PKA-independent PLN-CaMKII pathway ↩ ↩²
doi:10.1007/s10741-019-09825-x · PMID:31407140 · review · model: human + animal cardiovascular aging · β-AR downregulation and reduced cAMP response in aged cardiac tissue; GRK2/Gαi upregulation as mechanism; not_oa in archive unverified-source ↩
doi:10.1016/j.cell.2007.07.016 · PMID:17662939 · in-vivo (mouse) · model: mixed background AC5-KO · AC5-KO mice show ~30% median lifespan extension, improved exercise tolerance, resistance to heart failure and obesity; not independently verified against PDF (cited via Enns 2010) needs-replication ↩ ↩²
doi:10.1111/acel.13055 · PMID:31668016 · in-vitro + in-vivo (mouse) · model: hippocampal neurons (5 div primary), tau-overexpressing mice (AAV-syn-hTau-EGFP into CA3, n=15/group) · overexpressed full-length wild-type human tau inhibits PKA via nuclear proteasome-dependent PKAR2α (RIIα) elevation: hTau disrupts PA28γ-20S proteasome complex → PKAR2α accumulates in nuclear fraction → PKA inhibited → pCREB(Ser133) and pGluA1(Ser845) reduced → memory deficits; rolipram (PKA agonist) rescues ↩
doi:10.1016/j.exger.2013.08.004 · PMID:23994518 · in-vivo (rat) · model: aged Fischer 344 rats, endurance training protocol · exercise restores p-CREB and PGC-1α in aged skeletal muscle; not_oa in archive unverified-source ↩
doi:10.1155/2021/6695613 · PMID:34257818 · in-vivo (mouse) + in-vitro · model: D-galactose aging model, CD1/ICR mice (NOT C57BL/6), n=12/group behavioral, n=6/group histology; dose: PTX 60 mg/kg/d i.p. × 4 weeks; D-gal 100 mg/kg/d s.c. × 8 weeks · pentoxifylline activates cAMP-CREB pathway → Nrf2 + PGC-1α protein/mRNA ↑ → antioxidant (HO-1, NQO1, SOD2, CAT) and mitochondrial biogenesis markers (CS activity, mtDNA copy number, TFAM) restored in hippocampus; Nrf2-KO mice confirmed Nrf2 dependence ↩
doi:10.1038/s41467-019-12425-w · PMID:31659167 · in-vivo (worm) + in-vitro · model: C. elegans N2 · hydralazine binds and stabilizes PKA catalytic subunit (PRKACA/KIN-1) → regulatory subunit dissociates → PKA ACTIVATED (not inhibited) → SIRT1/SIR-2.1 phosphorylated/activated (NAD-independent) + SIRT5/TFAM upregulated → mitochondrial biogenesis ↑ → ~25% median lifespan extension (exact value in Table S1; KIN-1 knockdown abrogates lifespan benefit confirming PKA-dependence) ↩ ↩²

🧬 Aging Wiki

Explorer

camp-signaling